Abstract Substance use disorders (SUDs) remain problematic as many individuals are untreated or do not benefit from the currently available interventions. Thus, there is an urgent need to develop novel pharmacological interventions to treat SUDs. Evidence suggests that the female sex hormone, progesterone, attenuates the craving for and the euphoric effects of drugs of abuse. Research to date has demonstrated that progesterone may modulate responses to drugs of abuse and may have utility as a novel treatment for SUDs. A literature search was conducted to identify and examine studies that administered exogenous progesterone. Sixteen publications were identified, exploring the utility of exogenous progesterone or its metabolite, allopregnanolone, among a range of substances, including amphetamines (one study), benzodiazepines (one study), cocaine (nine studies), and tobacco/nicotine (five studies). Results indicated that exogenous progesterone and, its metabolite allopregnanolone, demonstrated preliminary efficacy as a treatment for substance use in both men and women. Notably, progesterone appears to target negative affect and augment cognitive functioning, especially among female substance users. Additional research is needed to explore the potential use of exogenous progesterone and allopregnanolone in the treatment of SUDs, including that associated with alcohol and opioids, but considering the current promising findings, exogenous progesterone and allopregnanolone may have utility as novel pharmacological treatments for SUDs.
Introduction
of novel treatment approaches for SUDs remains an important goal.
Studies examining the impact of sex and cycle phase on SUDs demonstrate that the female sex hormone, progesterone, modulates responses to drugs of abuse and may serve as a novel intervention to treat SUDs. Most notably, evidence suggests that progesterone may attenuate craving and euphoric effects from some drugs of abuse and improve response inhibition function [5] [6] [7] [8] [9] . These findings led to the possibility that progesterone and its metabolites may have utility in the development of novel SUD treatment approaches. The purpose of the present article is to identify and review the current literature surrounding the potential utility of exogenous progesterone administration for the treatment of SUDs. The article begins with a brief review of the sex differences (male vs. female) associated with the development and treatment of SUDs and then explores the underlying mechanisms associated with these differences. We then review the neurobiological effects of female sex hormones, cycle-phase effects, and the clinical/ pre-clinical studies examining the impact of cycle phase on addictive behaviors in female-only samples. Following this, we review studies that have examined the use of exogenous progesterone as an effective treatment for SUDs. We conclude with a discussion of the future directions of progesterone treatment as a pharmacological intervention for SUDs. Of note, the article primarily focuses on progesterone, given the current evidence that it may attenuate craving and subjective positive drug responses [5] [6] [7] [8] [9] . However, the review briefly provides background information on estradiol, another female sex hormone, to provide context for the information presented in this review.
Sex Differences in Substance Use Disorder

Preclinical Evidence of Sex Differences in Acquisition, Maintenance, and Extinction of Drug Use
The sex differences observed in pre-clinical studies are seen across all phases of substance use, including in the acquisition of drug-taking behavior, as well as during the maintenance and extinction of drug use . These findings indicate that there are unique biological and behavioral differences associated with SUDs among male and female individuals. In animal models, self-administration paradigms are used to model aspects of SUDs associated with binge drug taking, intoxication, and escalation of drug use. Generally, animal models have shown that female animals acquire self-administration of drugs of abuse including alcohol, cocaine, nicotine, and opioids, more rapidly than male animals [10] [11] [12] . Female rats have been shown to voluntarily consume more alcohol than male rats and they generally acquire self-administration of cocaine and heroin more rapidly than male rats on the same reinforcement schedule [13] [14] [15] . Female animals, compared with male animals, also have higher levels of responding in both fixed and progressive-ratio schedules (i.e., work harder to selfadminister) for nicotine, cocaine, methamphetamine, and opioid self-administration, suggesting a greater motivation to obtain drugs [10, 11, [16] [17] [18] .
In preclinical models of relapse, female rats have been shown to have a higher rate of drug-seeking behavior than male rats during a drug-induced reinstatement procedure for cocaine [19, 20] . Overall, female rats exhibit increased sensitivity for drug-, cue-, and stress-induced reinstatement across substances, including alcohol, cocaine, and methamphetamine, suggesting that female rats are at an increased risk for relapse [10, [21] [22] [23] [24] . Sex differences have also been observed in preclinical models of withdrawal, as female animals consuming cocaine, cannabinoids, and nicotine exhibit more pronounced physical and behavioral symptoms than male animals [e.g., [25] [26] [27] . Notably, higher rates of toxicity (e.g., rapid weight loss or death) have been observed among female rodents during an initial withdrawal period from intravenous cocaine [20] ; however, studies have also demonstrated that male animals when compared to female animals, have shown marked symptoms when withdrawing from alcohol, opioids, and other psychostimulants [e.g., [28] [29] [30] [31] .
Overall, in animal models of drug dependence, female animals generally demonstrate quicker acquisition, increased consumption, and greater sensitivity to reinforcing effects in various drugs of abuse including alcohol, cocaine, nicotine, and opioids than male animals. Thus, the present evidence suggests a greater vulnerability to addiction in female animals [10] [11] [12] [13] [14] [15] [19] [20] [21] [22] [23] [24] . Given this highlighted increase in the susceptibility towards addiction, unique mechanisms may account for these observed sex differences and these mechanisms may present potential treatment targets for SUDs.
Clinical and Epidemiological Evidence of Sex Differences in Substance Use Disorder Prevalence
Current reports indicate that while men use substances at a higher rate than women, the sex gap is narrowing [32] . Lifetime prevalence for a SUD is approximately 12.3% for men and 7.7% for women in USA; however, 12-month prevalence rates illustrate this narrowing gap, with 4.9% of men and 3.0% of women meeting diagnostic criteria for a SUD [4] . For example, marginal differences are observed for a 12-month prevalence rate for cocaine use disorder (men 0.5%; women 0.2%) and current cigarette use (men 16.7%; women 13.6%) [4, 33] . Additionally, data suggest increasing rates of alcohol consumption among women, with 47.7% of women reporting drinking at least five drinks per day over the past year from 2012 to 2013, while 33.5% of women reported the same drinking rate in 2001-2002 [34] . These rates are especially problematic as recent evidence demonstrates that women escalate to problematic drug use faster than men in a telescoping course [11] . Women exhibit shorter durations from onset of substance use, to regular use and treatment entry, across substances including alcohol, cannabis, cocaine, and opioids [35, 36] . Women also encounter more significant medical, psychiatric, and social consequences related to their drug use than men [32] . For instance, women are more likely to develop organ damage and are at an increased risk of cardiovascular disease, stroke, and lung cancer than men [37, 38] . Furthermore, substance use significantly impacts gynecological health, including experience of amenorrhea, irregular menses, and cramping [38] .
Despite these severe health consequences, less than 20% of women receive treatment for SUDs [39, 40] . Overall substance users experience high rates of relapse, with estimates ranging from 50 to 90% [41] . Women exhibit increased rates of relapse and are more likely to utilize substances to relieve negative affect than men [42] ; thus, there are likely additional barriers to abstinence among women, including increased susceptibility to craving, as well as negative affect and stress reactivity [43] [44] [45] . Targeting these potential barriers may prove to be beneficial when developing novel pharmacological interventions for SUDs.
Sex Differences in the Response to Subjective Effects of Drugs of Abuse
A large body of evidence supports unique sex differences in response to drugs of abuse. Across various drugs of abuse, it has been postulated that men use drugs for their reinforcing effects, whereas women are more likely to use drugs for affect and stress regulation [46, 47] . For instance, it is well established that female tobacco smokers are more likely than male tobacco smokers to smoke for the alleviation of negative affect and relapse rates in women are associated more significantly with higher levels of stress than men [48] [49] [50] [51] . Female smokers have been found to experience greater subjective negative affect, craving, arousal, and stress reactivity in response to stress cues and they smoke more quickly following negative mood induction than male smokers [48] [49] [50] [51] . Furthermore, men endorse motivation to ameliorate craving as a predictor in tobacco relapse; however, in women, depressive mood, anxiety, anger, and perceived stress have been found to be associated with relapse [49] . Female tobacco smokers have been found to be less sensitive to the pharmacological effects of smoking than male tobacco smokers, but are more sensitive to non-pharmacological, as well as subjective stimuli, implying that these areas are important when developing novel cessation therapeutics [52] . These sex differences are also observed in the abuse of other substances. For example, among alcohol-dependent individuals, women demonstrated a greater sensitivity to stress-induced alcohol craving and anxiety compared with men [53] . Similarly, women compared to men, have diminished euphoria in response to intravenous nicotine and smoked cocaine [54, 55] . These findings highlight unique sex differences that may inform sex-specific pharmacological and behavioral interventions for SUDs.
Overview of Female Sex Hormones
Before reviewing the effects of progesterone on SUD, it is important to summarize the physiological functions of both progesterone and estradiol, to provide context for the present review.
Progesterone
Progesterone is a 21-carbon hormone derived from cholesterol that is synthesized in the gonads, as well as adrenal glands (see Fig. 1 ). Progesterone is well known for its reproductive functions in women, especially in the maintenance of pregnancy, while its functions in men are less clear [56] . Progesterone and its metabolites, allopregnanolone and pregnanolone, are also called 'neurosteroids' as they are synthesized in the brain de novo from cholesterol [57] . These hormones are highly lipophilic and easily cross the blood-brain barrier [58] . As demonstrated in multiple studies over the past decades, progesterone and its metabolites regulate neuronal signaling and function through genomic and nongenomic actions [9, 57] . The genomic effects are mediated by two isoform progesterone receptors (PRs): PRA and PRB. Similar to other steroid hormones, progesterone regulates gene transcription through binding of intracellular PRs. Once activated, PRs interact with a nuclear transcription factor through the progesterone response element, which regulates the transcription of multiple genes [59, 60] . The non-genomic effects of progesterone are likely mediated through interaction with multiple neurotransmitter receptors including sigma, glutamate, GABA A , and nicotinic receptors (a4b2, a5) [9, [61] [62] [63] [64] .
Allopregnanolone has positive modulatory effects on GABA A receptors and thereby enhances GABA transmission. GABAergic transmission is the main inhibitory neurotransmitter system in the brain and has been proposed to result in diminished drug reward [9] . In addition, two other types of PR that are distinct from classical PRs have also been identified: membrane PRs and the progesterone membrane receptor component. The function of these two receptor types remains to be determined [65] .
Estradiol
Estradiol is another female sex hormone produced primarily in the gonads, with other tissues producing smaller amounts, including the adrenal glands, kidney, adipose tissue, and the brain. Derived from cholesterol, estradiol is a naturally occurring form of estrogen, and is the most potent form present during the reproductive years [66] . With specific receptor sites throughout the central nervous system, estradiol has been shown to be associated with alterations with several neurotransmitter systems. For instance, the binding of estrogen is associated with an increase in density of the serotonergic and dopamine receptors [67] . These alternations in neurotransmitter systems have implicated estradiol as a mediator for addictive behaviors and reward responses.
Menstrual and Estrous Cycle Descriptions
The human menstrual cycle lasts between 25 and 35 days, with a median cycle length of 28 days [68] . The cycle is typically divided into the follicular and luteal phases, separated by ovulation, marked by a preovulatory surge in luteinizing hormone. The cycle begins with menses, marking the onset of the follicular phase. The follicular phase is characterized by elevated levels of estradiol, with levels ranging from 20 to 80 pg/mL during the early to mid-follicular phase. Estradiol levels peak at 200-500 pg/ mL during the preovulatory luteinizing hormone surge before decreasing, with levels ranging from 60 to 200 pg/ mL during the mid-luteal phase. Conversely, progesterone is at its nadir during the follicular phase, with levels less than 1.5 ng/mL. Levels begin to increase prior to the preovulatory luteinizing hormone surge, peaking during the mid-luteal phase, where progesterone is typically higher than 7 ng/mL. Of note, during pregnancy, serum progesterone raises to 40 ng/mL by the end of the first trimester, reaching a peak, approximately 150 ng/mL, at full-term pregnancy [69] .
The rodent estrous cycle typically occurs over 4 days and is divided into the proestrus, estrus, metestrus, and diestrus phases, with ovulation occurring between proestrus and estrus. Progesterone levels peak twice, during the evenings of proestrus and metestrus phases, with levels ranging from 65 to 200 nM at their peak [70, 71] . Lower stable levels of progesterone range from 10 to 20 nM during the remainder of the cycle. Serum estradiol levels peak during the afternoons (beginning at noon) of the metestrus and proestrus, with peak levels ranging from 130 to 325 pM. However, estradiol levels fall to less than 10 pM by ovulation [70, 71] .
Preclinical and Clinical Studies of the Effect of Female Sex Hormones on Drug Use
Preclinical and clinical studies exploring the underlying mechanisms of sex differences in SUDs have demonstrated that female sex hormones impact substance use and subjective substance use behaviors (e.g., withdrawal, response, and craving). The impact of fluctuations of female sex hormone levels across the menstrual/estrous cycles on substance use continues to be an active area of research.
Overall, it appears that estradiol augments drug reward, while progesterone attenuates such effects [9] .
Preclinical Evidence
Preclinical studies in female samples have demonstrated the cycle-phase effect on substance use, reward, and withdrawal, as well as the importance of actual female sex hormone levels regarding substance-use variables. It appears that estrogen may augment drug-seeking behavior and drug-reinforced responding, as previous studies have demonstrated that female rats with chemically or surgically blocked estrogen responded less for cocaine [72] . Furthermore, estradiol has been shown to augment cocaine acquisition in female rats, but when progesterone is administered concurrently with estradiol, this increase in responding is inhibited [73] . Administration of exogenous progesterone to female animals has been shown to decrease cocaine self-administration, resulting in a right shift of the cocaine dose-effect curve in primates and attenuating the escalation of cocaine self-administration in rodents [74, 75] . Furthermore, exogenous progesterone has been shown to decrease impulsive choice for cocaine, but not food among female rodents [76] . A review of cocaine extinction demonstrated that female rats in the estrous phase respond more during cocaine extinction than other phases, but exogenous estrogen enhanced cocaine reinstatement [77] . Overall, evidence suggests that exogenous progesterone displays anti-addictive effects in preclinical studies, as it attenuates effects in drug use across the phases of substance use, including acquisition, self-administration, and reinstatement/extinction.
Clinical Evidence
Clinical studies indicate that elevated levels of progesterone, as observed in the luteal phase (progesterone dominant) may decrease abuse-related effects of drugs of abuse, as well as increase the odds of abstinence from smoking cigarettes. Smoking cessation and subsequent relapse have been shown to vary by menstrual cycle phase, with several studies in female samples demonstrating that when non-pharmacological interventions are utilized, the luteal phase, compared to the follicular phase (estradiol dominant), is associated with better outcomes [78] [79] [80] . Further, higher progesterone levels during the luteal phase have been associated with a decreased urge to smoke and attenuated ratings of euphoria in female smokers [54, [80] [81] [82] . When looking at actual hormone levels in female smokers, as opposed to dichotomous menstrual cycle categorizations, increasing progesterone is associated with a 23% increase in the odds of abstinence among female tobacco smokers receiving medication treatment [83] . Preliminary evidence suggests that higher allopregnanolone levels are associated with a decrease in subjective negative affect following nicotine nasal spray in premenopausal women [84] . The association between progesterone and decreases in positive subjective ratings also extends to other drugs of abuse. In two previous studies, female cocaine users, who were in the luteal phase (progesterone dominant) of their menstrual cycle, demonstrated diminished responses to the subjective effects of cocaine (e.g., ''good drug effect'') when compared with those women in the follicular phase (estradiol dominant) of their menstrual cycle or men [5, 8] . Furthermore, among cocaine-dependent women, high endogenous progesterone levels were associated with attenuated drug craving and anxiety responses [85] . Similarly, healthy women had diminished subjective responses to oral d-amphetamine during the luteal phase, compared to the follicular phase [86] .
Additionally, research demonstrates that progesterone may attenuate stress response. Less susceptibility to stressand cue-related craving has been observed during the luteal phase, when progesterone levels are high, while reports of greater stress and arousal, as well as greater orbitofrontal cortex activation in response to smoking cues (e.g., increased relapse vulnerability), have been found during the follicular phase of the menstrual cycle [48, 84, [87] [88] [89] .
Preliminary evidence also suggests that progesterone positively impacts cognitive functioning, which would be of significant clinical importance in the treatment of SUDs, as impairments in cognitive control and other executive functions have been associated with poor treatment outcomes, including treatment dropout in both sexes [90, 91] . It is postulated that progesterone has cognitive-enhancing effects, as it has been shown to improve verbal working memory, as well as augment measures of sustained attention during the luteal phase, when progesterone levels are higher than the follicular phase [85, 92] . Together, these studies provide convincing evidence that high endogenous progesterone levels are associated with attenuated craving to smoke cigarettes, self-reporting of positive subjective responses to stimulant drugs, and stress reactivity in female individuals, as well as preliminary evidence of cognitiveenhancing effects within the context of SUDs.
Review of Studies of Progesterone Administration in the Context of Substance Use Disorders
Beginning with the identification of sex differences in substance use, both the preclinical and clinical literature consistently identify that female individuals have a greater vulnerability to addiction and are more sensitive to the reinforcing effects of substance use (particularly negative reinforcement) than male individuals [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] . Based upon the animal and human literature to date, there is evidence to suggest an inverse relationship between endogenous progesterone levels and substance use behavior in female individuals [9, 72-80, 85, 91, 92] . Further, higher endogenous progesterone levels in the luteal phase are also associated with attenuation of positive subjective effects of drugs and improved negative affect and cognitive functioning in women [5, 8, 48, 54, [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] .
Given the current evidence, exogenous progesterone may prove to be an effective intervention for SUDs. The present review examines the current literature surrounding administration of exogenous progesterone for licit and illicit substance use and explores its potential utility as a novel treatment for SUD.
Narrative Review Search
The present narrative review includes articles identified in a PubMed search from December 2016 through November 2017 to locate studies that administered exogenous progesterone within the context of substance use (e.g., to attenuate drug effects). Search terms included: 'progesterone, 'exogenous progesterone,' 'progesterone treatment,' and 'progesterone administration' AND at least one of the following: 'amphetamines,' 'alcohol,' 'cannabis,' 'cocaine,' 'drug use,' 'heroin,' 'marijuana,' 'methamphetamine,' 'nicotine,' 'opioids,' 'tobacco,' 'smoking,' 'substance use,' and 'substance use treatment.' Results were restricted to clinical trials. Additional manuscripts were identified by examining reference lists.
The search yield 137 relevant abstracts; each abstract was then reviewed to evaluate if the article met the following inclusion criteria: (1) published in English, (2) administered exogenous, natural progesterone at least once, and (3) included administration of a drug of abuse or conducted within a substance-using population. Excluded publications included those that described the impact of hormone levels (e.g., progesterone levels) on drug effects and outcomes without administration of exogenous natural progesterone. Additionally, commentaries on the utility and side effects of administering progesterone in healthcare settings were excluded. This resulted in a full article review of 17 manuscripts. The identified publications' full manuscripts were then reviewed by both authors for sample description, study paradigms, and drug/progesterone administration. These criteria resulted in a pool of 16 manuscripts, spanning investigations of amphetamines (one study), benzodiazepines (one study), cocaine (nine studies), and tobacco/nicotine (five studies); among these reports, all included a placebo-controlled condition. One report was eliminated from the present narrative review, as it detailed the administration of oral contraceptives, not exogenous progesterone. These reports included measures of drug use (i.e., ad lib/self-administration, abstinence, withdrawal symptoms), subjective/affect effects, physiological, stress (i.e., hypothalamic-pituitary-adrenal axis), and cognitive tasks. Studies are presented in Table 1 . Overall, evidence suggests that exogenous progesterone diminishes positive subjective drug effects. One study of both male and female (in the early follicular phase) smokers demonstrated that administration of progesterone (200 mg) was associated with lower ratings of ''drug liking'' than placebo [7] . Additionally, 200-and 400-mg doses of progesterone demonstrated lower ratings of ''drug strength'' regarding smoking [7] . Similarly, two additional studies of male and female (in the early follicular phase) smokers showed that a single dose of 200 mg of progesterone significantly diminished ratings on measures of ''good'' drug effects and ''drug liking,'' as well as increased ''bad'' drug effects, following nicotine administration (smoked self-administration or intravenous injection), when compared with placebo [55, 93] .
Regarding the subjective effects in response to cocaine administration in normally menstruating women in the follicular phase (scheduled 6-10 days following onset of menses), administration of progesterone (150 mg/day) over 4 days attenuated ''good drug'' and ''drug quality'' ratings when compared with men and women in the follicular phase receiving placebo [94] . A single dose of progesterone (200 mg) in female individuals in the early follicular phase was related to a diminished rating of ''feel the effect of last dose'' after smoked cocaine administration when compared with placebo treatment [95] . Finally, both male and female cocaine users reported attenuated subjective ratings of ''high'' and ''effect of last dose'', in response to intravenous cocaine in comparison to placebo after receiving two doses of oral progesterone (200 mg) [96] .
Conversely, in the one study of amphetamines to date, long-term administration of progesterone (200 mg/day over 3 days) enhanced positive subjective effects, as well as reports of ''good drug effect'' and ''drug liking'', when compared with the placebo condition [97] .
Thus, evidence indicates that progesterone pretreatment reduces the positive subjective effects from nicotine and cocaine use among male and female individuals. Given the limited research to date in amphetamines (one study), it is not yet clear if progesterone administration would be an effective means to attenuate subjective responses to these drugs. The effect of exogenous progesterone on subjective drug effects has not been studied for other substances of abuse. 
Drug-Induced Urges
Across clinical studies for cocaine and nicotine, administration of exogenous progesterone appears to attenuate craving ratings. Among a group of early abstinent, treatment-seeking cocaine users, those receiving daily doses of 400 mg (for 7 days) of progesterone reported lower levels of cocaine craving following a drug cue when compared with those receiving placebo treatment [98] . Furthermore, once the same sample was grouped based upon plasma levels of allopregnanolone, those women with increased levels of allopregnanolone reported an overall lower peak cocaine craving across drug-, stress-, and relaxing-cue conditions [99] . These findings also are consistent with studies conducted in cigarette smokers, where both male and female smokers receiving progesterone treatment reported attenuated craving for and/or urges to smoke, when compared with placebo treatment [7, 55, 93, 100] . Overall, evidence suggests that exogenous progesterone treatment reduces drug-induced cravings and urges.
Drug Use
Human Laboratory Studies
Only one study to date has shown a trend in decreased smoking behavior within a laboratory setting. In this study, following a single dose of progesterone (200 mg), female smokers (in the early follicular phase) demonstrated attenuated smoking, compared with placebo, during a selfadministration smoking paradigm, where they exchanged tokens valued at US$1-2 for two puffs of a cigarette [93] . Another study demonstrated that progesterone treatment (200 mg/day administered over 3 days), compared with placebo, was related to an increase in amphetamine choices over various monetary amounts (ranging from US$0.25 to US$64), as measured over nine discrete choices between drug and money during an established multiple-choice procedure [97] . Further, research among cocaine human laboratory studies provides no evidence that progesterone pretreatment (both long-term and single-dose administration ranging from 150 to 400 mg/session), as compared with placebo, affected cocaine use (measured via self-administration), plasma cocaine concentration, or pharmacokinetics [94] [95] [96] 101] . Laboratory results to date demonstrate that progesterone has a limited, if any, effect on reducing drug use or altering pharmacokinetics of drugs in both men and women.
Clinical Trials
Among trials of cocaine users, long-term administration of progesterone (ranging from 10 to 12 weeks of 100-300 mg/day of progesterone) when compared with placebo, resulted in a slight reduction in the probability of a positive urine drug screen for cocaine in women (including postpartum women), but not in men who were using cocaine while maintained on methadone [102, 103] . Two trials of postpartum tobacco smokers who were administered 400 mg/day of progesterone (duration of 4 or 8 weeks, respectively) showed increased rates of abstinence compared with those administered placebo medication [100, 104] . In another study, no differences in drug abstinence were observed following progesterone treatment (titrated to mean daily dose of 1983 mg) vs. placebo treatment among male and post-menopausal benzodiazepine users [105] . The limited evidence available supports that exogenous progesterone may assist in increasing abstinence among postpartum women who are either cocaine users or tobacco smokers, but continued studies are needed among other drugs of abuse in various participant populations.
Effects on Drug Withdrawal, Urges, and Affect
Withdrawal and Urges
Across studies of benzodiazepines and tobacco, exogenous progesterone (ranging from a single 200-mg/day dose to a mean daily dose of 1983 mg) as compared to placebo, did not attenuate withdrawal symptoms in women or men [55, 93, 105] . Conversely, progesterone treatment (either in a single dose of 200 mg or a 400-mg/day treatment over 12 weeks) vs. placebo treatment decreased cravings and urges to smoke in a range of populations, including men, women, and postpartum women [55, 93, 100] . However, this finding was not replicated in a randomized control study of cocaine use disorder, following 12 weeks of 100 mg/day of progesterone vs. placebo in postpartum women [103] . Thus, progesterone treatment may have utility in attenuating cravings and urges in male and female tobacco smokers, but additional research is needed in other substances of abuse.
Affect
There appears to be limited evidence to suggest that progesterone treatment changes measures of negative affect, depression, or anxiety. Several studies did not demonstrate significant changes in negative affect, depression, or anxiety from baseline, following progesterone treatment. There were no differences in progesterone treatment (single dose of 200 mg) vs. placebo in measures of depressive symptoms (e.g., the Profile of Mood States) in male and female tobacco or cocaine users [55, 96] . Additionally, there was no difference between 200 or 400 mg/day of progesterone treatment and placebo in two 12-week trials on the Edinburgh Postnatal Depression Scale in postpartum cocaine users or tobacco smokers [103, 104] .
However, one study demonstrated a relationship between high allopregnanolone levels and high positive emotion [99] . Further, another study demonstrated that progesterone pretreatment (200 mg/day for 3 days) when combined with amphetamine (10-20 mg doses) decreased state anxiety ratings [97] . Given this information, there is mixed evidence to date that exogenous progesterone, administered within a substance use context, augments negative affect, depression, or anxiety.
Stress Response
Hypothalamic-Pituitary-Adrenal Axis Hormones
In one study of male and female treatment-seeking cocaine users, those receiving progesterone (400 mg/day for 7 days) demonstrated decreased cue-induced cortisol responses and increased cue-induced ACTH responses vs. placebo treatment [98] . Further, when these participants were grouped based upon their plasma allopregnanolone levels, individuals with higher levels of allopregnanolone exhibited lower baseline levels of cortisol than those with lower levels; however, this group also exhibited a greater change in cortisol levels when presented with stress-inducing guided imagery [99] . These limited results demonstrated mixed evidence for the effect of exogenous progesterone on hypothalamic-pituitary-adrenal hormones.
Stress-Induced Affect
In terms of stress-induced affect changes, cocaine-dependent women receiving placebo at the start of their menstrual cycle, reported lower ratings of positive mood and decreased negative emotion following stress-cued imagery than women receiving progesterone (400 mg/day for 7 days) [98] . This, albeit, limited evidence suggests that progesterone may be protective against stress-induced affect.
Cardiovascular
In one study of oral amphetamine in healthy women, longterm administration of 200 mg/day of progesterone over 3 days attenuated both systolic and diastolic amphetamineincreased blood pressure with no observed treatment-group differences in heart rate [97] . One study of intravenous cocaine demonstrated a decrease in diastolic blood pressure among men and early follicular-phase women receiving progesterone (400 mg/session) vs. placebo, with no effect on systolic blood pressure or heart rate after intravenous cocaine administration [96] . Women in the follicular phase who were administered 150 mg/day of exogenous progesterone for 4 days vs. placebo and then smoked cocaine, demonstrated decreased diastolic pressure following 25 mg of cocaine, but diastolic pressure increased following 12 mg of cocaine [94] . This study also illustrated that cocaine-induced increases in heart rate were attenuated in the group receiving progesterone compared with placebo treatment [94] . Similarly, a single dose of 400 mg, but not 200 mg of progesterone or placebo attenuated diastolic blood pressure in female tobacco smokers in the early follicular phase compared with male smokers; however, systolic blood pressure was not significantly affected in either sexes [7] . No significant treatment differences were observed in blood pressure (diastolic or systolic) or heart rate after a period of nicotine self-administration (intravenous nicotine and smoked nicotine) following a single dose of 200 mg of progesterone vs. placebo in the two remaining nicotine studies that reported cardiovascular measures [55, 93] . Thus, progesterone administration demonstrated mixed evidence on its ability to attenuate cardiovascular effects of substances of abuse.
Cognitive Function
Progesterone has been shown to have positive cognitive inhibitory effects. In one study, following 7 days of 400-mg/day progesterone administration, women and men abstaining from cocaine use had improved inhibitory performances, as measured by the Stroop Color Word Task [98] . Additionally, among these abstinent treatment-seeking cocaine users, those with higher levels of allopregnanolone, also demonstrated higher Stroop Color/Word scores following both drug-and stress-cued imagery relative to pre-imagery scores when compared with participants with low levels of allopregnanolone [99] . Female tobacco smokers in the early follicular phase receiving a single dose of 200 mg of progesterone vs. placebo also exhibited improved Stroop performance, but no improvement was observed in men [7] .
Progesterone treatment (a single dose of 200 mg) has been shown to improve cognitive performance on the Digit Symbol Substitution Test in both male and female (in the early follicular phase) abstinent tobacco smokers when compared with placebo or 400 mg of progesterone [7] . Conversely, both the Digit Symbol Substitution Test and delayed memory task scores were impaired following 200 mg/day of progesterone pretreatment vs. placebo over 3 days, in a study of follicular-phase women who were administered oral amphetamine; no other impulsivity measures (i.e., Immediate Memory Task; GoStop Task; Delay Discounting Task) were impaired [97] .
Additionally, there is preliminary evidence that exogenous progesterone may improve regulation of some emotional processing mechanisms. One study has demonstrated that long-term administration of 400 mg/day for 7 days vs. placebo improved scores on the Thought Facilitation Task scale on the Mayer-Salovey-Caruso Emotional Intelligence Test in early abstinent cocaine users who also abused alcohol; there was no observed sex difference between male and female individuals [106] .
Discussion
Overall, findings to date suggest that progesterone has utility as a novel pharmacological treatment for SUDs. While little evidence suggests that exogenous progesterone reduces drug use in laboratory studies, there is evidence to suggest that progesterone may prevent relapse and improves abstinence from cocaine and cigarette smoking [7, 102] . Most striking is the available clinical evidence to demonstrate that exogenous progesterone increases abstinence among postpartum women abusing cocaine or tobacco cigarettes. Yonkers and colleagues (2014) reported that women receiving placebo medication had more selfreported cocaine use when compared with those receiving progesterone [103] . Among tobacco smokers, two studies have demonstrated that those receiving progesterone had higher rates of abstinence, with one study reporting a slower rate of relapse at the 3-month follow-up among those taking exogenous progesterone [100, 104] . These findings suggest that progesterone may be a potential treatment option to improve abstinence and prevent relapse especially in postpartum female individuals abusing cocaine and nicotine. Whether progesterone may be useful for the treatment of other drugs of abuse remains to be determined in future studies.
While future studies are needed to investigate the utility of exogenous progesterone to treat a range of substances, the present review shows that progesterone may have the potential to treat SUDs, given the promising findings to date in reducing subjective drug ratings and craving in cocaine and nicotine. Progesterone treatment in both male and female individuals generally decreased positive subjective ratings of both nicotine and cocaine craving and urges to smoke [7, 55, [93] [94] [95] [96] [98] [99] [100] . These results are consistent with preclinical and clinical evidence demonstrating that endogenous progesterone attenuates reports of drug craving, urges, and euphoric drug effects [6, 10] . These findings highlight the potential utility of exogenous progesterone in the pharmacological treatment of SUDs. Additionally, while these positive findings appear across the treatment of both men and women, given the difficulty women have in successful SUD treatment outcomes, the results of exogenous progesterone are especially promising in women and need to be studied further [42] [43] [44] [45] .
Despite these promising results, the underlying mechanisms for these observed effects have yet to be elucidated. One postulation may include the role of progesterone in attenuating negative affect and stress reactivity. The substance use literature consistently postulates that women are more likely to use substances to alleviate negative affect, including stress, than men [32, 42, 107, 108] . One study demonstrated that women receiving placebo in comparison to progesterone treatment reported lower ratings of positive mood and higher ratings of negative emotion following stress induction [98] . Thus, it may be possible that progesterone dampens such reactivity and offers a potential treatment target for individuals abusing substances.
Another possible underlying mechanism is the effects of progesterone on cognitive functioning. The current literature indicates progesterone has positive cognitive inhibitory effects on drug-and stress-cued response among individuals abusing tobacco and cocaine [7, 98] . Both the clinical and preclinical literature illustrate that progesterone and its metabolites augment learning and memory through neuronal activity [109] . This suggests that progesterone may attenuate deficits in learning and memory processes, thus assisting in the treatment of SUDs [58] . However, we are not aware of any studies demonstrating that the beneficial effects of progesterone on drug use is mediated by either improvement of negative affect or cognitive function.
Future Directions
Given the current promising results, future research needs to focus on elucidating the underlying mechanisms, including the neurobiological underpinnings of the effects of progesterone. This will assist in the identification of the patient populations that will most benefit from its use. For instance, the attenuating effect on negative affect and stress reactivity may allow exogenous progesterone to be further developed as a pharmacological intervention to target affect/stress and augment existing substance use interventions in women. Preliminary evidence suggests that exogenous progesterone and a psychosocial intervention had therapeutic promise among women, notably postpartum women, and the present results illustrate that administration of progesterone may augment response to current SUD interventions [103] . However, additional research with larger sample sizes and in other licit and illicit substances including alcohol and opioids is needed. More research is also needed to evaluate the role of progesterone in treating male individuals with SUDs. Additionally, given the overlapping mechanisms, including reward pathways, the utility of exogenous progesterone for the treatment of behavioral and food addictions should also be explored [110] .
Furthermore, while progesterone has been linked with attenuating drug craving, reward, and negative affect in both the clinical and preclinical literature, these effects have not been consistently robust. While the present results are promising and illustrate beneficial effects of progesterone in both sexes, it is likely that exogenous progesterone functions differently in men and women. Thus, there are many additional questions that need to be answered as exogenous progesterone is developed as a potential pharmacological intervention. For instance, both pre-clinical and clinical work suggests that progesterone decreases drug reward and positive subjective drug effects while also attenuating negative affect in female individuals, with effects surpassing those seen in male individuals [94] . It is unclear what may account for these observed differences. Future research should explore the potential impact of reward processing in male individuals, considering potential modulating factors, including impulsivity and stimulation. These studies would lead to better informed and targeted, sex-sensitive pharmacological interventions.
Research is also needed to examine the utility of progesterone's metabolite, allopregnanolone as a treatment for SUDs among women, given that it has demonstrated some effectiveness in improving negative affect in this population. For instance, one recent study demonstrated that among pregnant women, low serum levels of allopregnanolone were associated with increased self-rated depression scores, suggesting that high serum levels of allopregnanolone may be protective against depression [111] . In previous studies, allopregnanolone has been associated with decreased negative affect and this effect is likely associated with this metabolite's modulation of the GABA A receptor [9] . A recent study demonstrated that intravenous allopregnanolone significantly improved depression ratings among women with postpartum depression [112] . Additionally, higher allopregnanolone levels were associated with lower levels of baseline cortisol and positive inhibitory effects in drug and stress cues [106] . It appears that allopregnanolone may also have utility in targeting negative affect and stress reactivity among female substance users as a pharmacological strategy to augment current substance use treatments. Thus, additional research is needed to investigate the role of allopregnanolone in the treatment of SUDs.
Conclusion
The present narrative review details evidence that progesterone has utility in the treatment of SUDs in both men and women. The findings presented here support further investigation of progesterone as a novel pharmacological intervention to improve the treatment for SUDs. Exogenous progesterone has demonstrated preliminary utility to potentially target negative affect, which may most benefit women with SUDs, as this population shows vulnerability to the effects of negative affect and stress reactivity on substance use. Furthermore, exogenous progesterone was shown to augment cognitive functioning in both men and women, which offers the opportunity to enhance current treatment intervention outcomes. Additional research on hormonal therapy for SUDs is needed to expand the generalizability of the present results across substances of abuse and to test the utility of exogenous allopregnanolone among various populations.
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